DDW Editor Reece Armstrong speaks to Josh Mandel-Brehm, CEO of CAMP4 Therapeutics, about challenges in the discovery and development of RNA therapeutics. RA: Why has regulatory RNA historically not been exploited as a therapeutic target?  JMB: Historically, RNA has been viewed primarily as a messenger — a passive intermediary between DNA and proteins. But with […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!